Abstract
Androgens are required to maintain the integrity of the prostate and the survival of androgen dependent epithelial cells within the gland. Anti-androgens are the primary treatment strategy for non-localized prostate cancer, but ultimately fail over time with the development of androgen independent tumors. Estrogens affect the growth and development of the prostate and may affect the development of prostate cancer. Because of the side effects of estrogen treatment alternative therapies include the use of phytoestrogens as chemopreventative and chemotherapeutic treatment modalities. Phytoestrogens, can cause growth arrest and in some cases apoptosis in prostate cancer cells in vivo and in vitro. This may be due to the estrogenic properties of the compounds or alternative mechanisms of action. A number of phytoestrogens have been shown to have anti-androgenic effects and anti-oxidant activities. Other mechanisms include inhibition of 5α- reductase, 17β-hydroxysteroid dehydrogenase, aromatase, tyrosine specific protein kinases and DNA topoisomerase II. This review examines the possible relation between phytoestrogens and prostate cancer and their possible use in prostate cancer prevention or management.
Keywords: phytoestrogens, prostate cancer, estrogen receptor, flavonoids, lignans, stilbenes, chemoprevention, chemotherapy
Current Drug Targets
Title: Phytoestrogens and Prostate Cancer
Volume: 4 Issue: 3
Author(s): Colm Morrissey and R. William G. Watson
Affiliation:
Keywords: phytoestrogens, prostate cancer, estrogen receptor, flavonoids, lignans, stilbenes, chemoprevention, chemotherapy
Abstract: Androgens are required to maintain the integrity of the prostate and the survival of androgen dependent epithelial cells within the gland. Anti-androgens are the primary treatment strategy for non-localized prostate cancer, but ultimately fail over time with the development of androgen independent tumors. Estrogens affect the growth and development of the prostate and may affect the development of prostate cancer. Because of the side effects of estrogen treatment alternative therapies include the use of phytoestrogens as chemopreventative and chemotherapeutic treatment modalities. Phytoestrogens, can cause growth arrest and in some cases apoptosis in prostate cancer cells in vivo and in vitro. This may be due to the estrogenic properties of the compounds or alternative mechanisms of action. A number of phytoestrogens have been shown to have anti-androgenic effects and anti-oxidant activities. Other mechanisms include inhibition of 5α- reductase, 17β-hydroxysteroid dehydrogenase, aromatase, tyrosine specific protein kinases and DNA topoisomerase II. This review examines the possible relation between phytoestrogens and prostate cancer and their possible use in prostate cancer prevention or management.
Export Options
About this article
Cite this article as:
Morrissey Colm and G. Watson William R., Phytoestrogens and Prostate Cancer, Current Drug Targets 2003; 4 (3) . https://dx.doi.org/10.2174/1389450033491154
DOI https://dx.doi.org/10.2174/1389450033491154 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances and Developments in Treatment Strategies Against Pancreatic Cancer
Current Clinical Pharmacology Mechanisms for Targeted Delivery of Nanoparticles in Cancer
Current Pharmaceutical Design The Potential of Peroxisome Proliferator-Activated Receptor γ (PPARγ) Ligands in the Treatment of Hematological Malignancies
Mini-Reviews in Medicinal Chemistry An Overview of Emerging Immunotargets of Genitourinary Tumors
Current Drug Targets The Effects of Weightlessness on the Human Organism and Mammalian Cells
Current Molecular Medicine Saffron-Based Crocin Prevents Early Lesions of Liver Cancer: In vivo, In vitro and Network Analyses
Recent Patents on Anti-Cancer Drug Discovery The Pro-Survival Function of Akt Kinase can be Overridden or Altered to Contribute to Induction of Apoptosis
Current Cancer Drug Targets Scaling Down SAGE: from miniSAGE to microSAGE
Current Pharmaceutical Biotechnology A Trojan Horse in Drug Development: Targeting of Thapsigargins Towards Prostate Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in the Analyses of Phytoestrogens and Their Role in Human Health
Current Pharmaceutical Analysis Bone Target Radiotracers for Palliative Therapy of Bone Metastases
Current Medicinal Chemistry Patent Selections
Recent Patents on DNA & Gene Sequences Sanguinarine: A Double-Edged Sword of Anticancer and Carcinogenesis and Its Future Application Prospect
Anti-Cancer Agents in Medicinal Chemistry Apoptotic Potency of Angiostatic Compounds in the Treatment of Cancer
Current Pharmaceutical Biotechnology Microbiological Detoxification of Mycotoxins: Focus on Mechanisms and Advances
Infectious Disorders - Drug Targets From Proteins to Nucleic Acid-Based Drugs: The Role of Biotech in Anti-VEGF Therapy
Anti-Cancer Agents in Medicinal Chemistry Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design Molecular Mechanisms of Pancreatic Cancer Dissemination: The Role of the Chemokine System
Current Pharmaceutical Design Pitx2 Expression Promotes p21 Expression and Cell Cycle Exit in Neural Stem Cells
CNS & Neurological Disorders - Drug Targets The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma
Current Pharmaceutical Design